| 13.73 -0.85 (-5.83%) | 09-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.84 | 1-year : | 23.32 |
| Resists | First : | 16.98 | Second : | 19.96 |
| Pivot price | 16 |
|||
| Supports | First : | 12.15 | Second : | 10.11 |
| MAs | MA(5) : | 13.59 |
MA(20) : | 16.41 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1.5 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 22.5  |
D(3) : | 16.7 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 49.97 | Low : | 12.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OBX ] has closed above bottom band by 19.1%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 14.72 - 14.8 | 14.8 - 14.88 |
| Low: | 12.93 - 13.02 | 13.02 - 13.09 |
| Close: | 13.6 - 13.74 | 13.74 - 13.87 |
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Tue, 29 Sep 2026
Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) Share Price, OBX Stock News, OBX Share Price & Updates - kalkine.ca
Sat, 26 Sep 2026
Obsidian Therapeutics, Inc. (OBX) cash flow - Yahoo Finance UK
Thu, 24 Sep 2026
OBX Technical Analysis & Stock Price Forecast - Intellectia AI
Fri, 11 Sep 2026
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error (OBX) - Seeking Alpha
Sat, 08 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN
Wed, 05 Aug 2026
Obsidian Therapeutics (OBX) Stock Price, News & Analysis $OBX - marketbeat.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 27.3 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -13.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -8.86 |
| PEG Ratio | 0 |
| Price to Book value | -1.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|